Edition:
United Kingdom

argenx Has Selected Second Target Under ENHANZE Technology Collaboration And License Agreement


Wednesday, 22 May 2019 

May 22 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME ANNOUNCES ARGENX HAS SELECTED SECOND TARGET UNDER ENHANZE® TECHNOLOGY COLLABORATION AND LICENSE AGREEMENT.HALOZYME WILL RECEIVE A $10 MILLION MILESTONE PAYMENT DURING CURRENT QUARTER FROM ARGENX FOR THIS TARGET NOMINATION.HALOZYME THERAPEUTICS- RECEIVE POTENTIAL FUTURE PAYMENTS OF UP TO $160 MILLION SUBJECT TO ACHIEVEMENT OF SPECIFIED DEVELOPMENT, REGULATORY, SALES-BASED MILESTONES.HALOZYME WILL ALSO RECEIVE MID-SINGLE DIGIT ROYALTIES ON FUTURE COMMERCIAL SALES PRODUCTS. 

Company Quote

16.19
-0.24 -1.46%
7:40pm BST